ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most suitable drugs for individual canine and feline blood cancers.
The startup, which centers on improving treatment outcomes of dogs and cats with cancer first, now aims to expand its precision medicine technology for human oncology applications.
“The ex-vivo live-cell technologies we developed for canine blood cancers are well-applied to the majority of types of human blood cancer as well as feline blood cancers,” co-founder and chief executive officer Sungwon Lim said in an interview with TechCrunch. “Also, the proven know-how acquired from developing AI algorithms in veterinary oncology streamlines the building of new predictive models in human oncology. The veterinary-to-human expansion is happening now at ImpriMed and will result in commercialization in one-two years.”
Comments